Meeting
2023 ASCO Annual Meeting
A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).
Authors
Mohammad O. Atiq
Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
Mohammad O. Atiq , Liza Lindenberg , Esther Mena Gonzalez , Baris Turkbey , Fatima Karzai , Megan Hausler , Lisa M. Cordes , Monique Williams , Amy Hankin , James L. Gulley , William Douglas Figg , Peter L. Choyke , Ravi Amrit Madan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Epidemiology/Outcomes
Clinical Trial Registration Number
NCT05588128
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5101)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5101
Abstract #
TPS5101
Poster Bd #
193b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.
First Author: Luke T. Nordquist
Poster
2024 ASCO Genitourinary Cancers Symposium
PSMA PET imaging for evaluation of recurrent or persistent prostate cancer after primary prostate radiation.
First Author: Richard Bennett IV
Poster
2015 ASCO Annual Meeting
PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy.
First Author: Tobias Maurer
Poster
2024 ASCO Genitourinary Cancers Symposium
Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.
First Author: Ahmed M. Mahmoud